Drug intelligence / Profile preview

SAR113244

Development stage: Discontinued
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SAR113244 is a biologically engineered monoclonal antibody developed by Sanofi for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. It acts as an antagonist of the C-X-C chemokine receptor type 5 (CXCR5), targeting overactive immune cells implicated in lupus pathogenesis. The drug was designed for subcutaneous injection. Development was discontinued after early-phase clinical trials.

Other names: SAR 113244SAR113244SAR-113244

Targets

CXCR5 (C-X-C motif chemokine receptor 5)

Beyond the preview

Go deeper on SAR113244.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR113244.

Explore the full profile